1293940-27-8

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 39514-19-7 ethyl 1-benzyl-3-oxo-4-piperidinecarboxylate 
• 71233-25-5 ethyl 1-tert-butoxycarbonyl-3-oxopiperidine-4-carboxylate 
• 100-46-9 benzylamine 

Downstream Products

• 1293940-29-0 3-(benzylamino)piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 1166756-90-6 8-benzyl-3,8-diaza-bicyclo[4.2.0]octane-3-carboxylic acid tert-butyl ester 
• 928754-14-7 3,8-diaza-bicyclo[4.2.0]octane-3-carboxylic acid tert-butyl ester 
• 1293940-47-2 8-[4-(2-fluorophenyl)-2-methylthiazole-5-carbonyl]-3,8-diazabicyclo[4.2.0]octane-3-carboxylic acid tert-butyl ester 
• 1293940-44-9 8-(2,4-dimethylbenzenesulfonyl)-3,8-diazabicyclo[4.2.0]octane-3-carboxylic acid tert-butyl ester 
• 1293940-36-9 (biphenyl-2-yl)(3,8-diaza-bicyclo[4.2.0]oct-8-yl)methanone trifluoroacetic acid salt 
• 1293940-41-6 8-(biphenyl-2-carbonyl)-3,8-diazabicyclo[4.2.0]octane-3-carboxylic acid tert-butyl ester 
• 1293938-35-8 (biphenyl-2-yl)(3-quinoxalin-2-yl-3,8-diazabicyclo[4.2.0]oct-8-yl)methanone 

Relevant academic research and scientific papers

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

Provided herein are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.